CORRECTED-BREAKINGVIEWS-Corporate America revels in Supreme Court windfall Corrects to show that the American Clinical Laboratory Association, not AdvaMed, is suing the FDA, in paragraph 8. The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Gabriel Rubin WASHINGTON, July 23 (Reuters Breakingviews) - The scales of justice have been tipped in favor of Corporate America.

FACTBOX-What disruptions have been reported after the global tech outage? Updates July 19 (Reuters) - A global tech outage that appeared to be related to issues at cybersecurity firm CrowdStrike CRWD.O and Microsoft MSFT.O affected operations at airports, airlines, banks and media outlets on Friday . Here is a list of disruptions that have been reported across sectors: AIRPORTS, AIRLINES Airports and airlines around the globe warned of delays and cancellations or switched to manual check-ins, wi

U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday. HIGHLIGHTS * Avidity Biosciences Inc RNA.O : Leerink Partners raises target price to $56 from $38 * Broadcom Inc AVGO.O : TD Cowen raises target price to $1,750 from $1,500 * Cara Therapeutics Inc CARA.O : Canaccord Genuity cut

U.S. RESEARCH ROUNDUP-Abbvie, Lionsgate Studios, UnitedHealth Group June 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Abbvie, Lionsgate Studios and UnitedHealth Group, on Wednesday. HIGHLIGHTS * Abbvie Inc ABBV.N : HSBC raises to buy from hold * Crowdstrike Holdings Inc CRWD.O : BTIG cuts target price to $402 from $432 * Lionsgate Studios LION.O : Seaport Research Partners initiates coverage with neutral rating

Sherlock Bio evaluates over-the-counter rapid test for STIs, aims launch in 2025 By Bhanvi Satija May 30 (Reuters) - Sherlock Bio said on Thursday it had begun a trial of its over-the-counter rapid test for detecting sexually transmitted infections (STI) such as chlamydia and gonorrhea, and aims to launch it by mid-2025. The Massachusetts-based startup expects to become the first to launch a prescription-free rapid test for the infections, which affected 2.3 million people in the United States i